Aims: To evaluate the combination of NucliSENS magnetic extraction and NucliSENS analytic specific reagents (bioMérieux, Marcy L’Etoile, France) for the detection of respiratory syncytial virus (RSV) from a variety of respiratory samples.
Methods: Nucleic acids (NA) from pediatric samples (n=603) and a RSV specific inhibition control (R-IC) were co-extracted using the miniMAG and/or the easyMAG. Nucleic acid sequenced based amplification (NASBA) and molecular beacon detection of RSV and R-IC were performed using NucliSENS ASRs (NRSVA) and the NucliSENS EasyQ Analyzer. NRSVA results were compared to R-Mix culture and direct fluorescent antibody detection (DFA).
Results: NRSVA analytical specificity was 100%. NRSVA limit of detection was 5-20 RNA copies/reaction. Pre discordant analysis, sensitivity, specificity, PPV and NPV were, respectively, for R-Mix (64.7%, 100%, 100%, 94.5%); DFA (98.8%, 99.0%, 94.4%, 99.8%); NRSVA (94.1%, 95%, 75.5%, 99%). After discordant analysis, sensitivity, specificity, PPV and NPV were, respectively, for R-Mix (56.7%, 100%, 100%, 92.3%); DFA (87.6%, 99.2%, 95.5%, 97.7%); NRSVA (93.8%, 97%, 85.9%, 98.8%). RSV was detected in 17.8% of the samples and in 7 co-infections. Children with proven RSV infection, compared to children without a pathogen identified, had shorter median hospitalization stays (2 days versus 3 days, P=0.035), used less antibiotics (54% versus 69%) and shorter durations of antibiotic therapy (6.2 days versus 9.3 days, P=0.021), respectively.
Conclusions: NRSVA is sensitive and specific for RSV detection in respiratory samples. The R-IC monitored the test process, including NA extraction, target amplification and detection. The rapid detection of respiratory pathogens can foster appropriate patient management.